Skip to content

    Lung Cancer Health Center

    Font Size

    Lung Cancer Drug Crizotinib Shows Promise

    57% of Patients With Advanced Disease Had Tumors Shrink After Treatment
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    Oct. 27, 2010 -- An experimental drug is showing promise as a targeted treatment for lung cancer patients with a specific genetic abnormality.

    In an early clinical trial, nearly 57% of patients with very advanced non-small-cell lung cancer (NSCLC) treated with the drug crizotinib for two months saw their tumors shrink and 33% saw their tumors stabilize.

    Most had failed at least one previous round of traditional chemotherapy and some had undergone three or more previous rounds.

    Only about 10% of patients with advanced lung cancer respond to approved second-line chemotherapy regimens.

    The findings, which appear today in the New England Journal of Medicine, raise hopes that targeted treatments will transform cancer treatment in the future, experts say.

    “These are really exciting findings, and I don’t say that about all that many studies,” American Cancer Society Deputy Chief Medical Officer Len Lichtenfeld, MD, tells WebMD. “This really has the potential to be a game changer for a select group of patients with a disease that is very difficult to treat.”

    About 5% of Patients Could Benefit

    Crizotinib works by blocking the anaplastic lymphoma kinase (ALK) protein, a genetic abnormality believed to promote tumor growth found in about 5% of non-small-cell lung cancer patients. The abnormality is most common in nonsmokers and younger patients.

    About 10,000 of the 222,000 Americans diagnosed with non-small-cell lung cancer each year could be expected to have the genetic abnormality.

    In the newly published early-phase trial, researchers identified 82 lung cancer patients with the mutation out of 1,500 screened.

    When these patients were treated with the experimental drug, 47 (57%) saw their tumors shrink, and tumor growth stopped in 27 (33%) others.

    Sixty-three patients continued on the drug past the trial assessment period, and some have remained on it for more than two years.

    Unlike chemotherapy, there were few side effects with the targeted treatment. And many patients experienced improvement in symptoms related to their cancer after just a few weeks on the drug, researchers report.

    “This therapy is allowing patients to function without pain or a constant cough,” researcher Eunice Kwak, MD, PhD, of Massachusetts General Hospital, says in a news release. “The most rewarding thing about treating patients with this drug is watching them change from being completely controlled by their cancer to resuming a very normal life.”

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
    Lung Cancer Risks Myths and Facts
    Woman getting ct scan
    Improving Lung Cancer Survival Targeted Therapy
    cancer fighting foods
    Lung Cancer Surprising Differences Between Sexes
    Pets Improve Your Health
    Vitamin D
    Lung Cancer Surgery Options